会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 45. 发明申请
    • Casing packoff system
    • 套管包装系统
    • US20060196680A1
    • 2006-09-07
    • US11069264
    • 2005-03-01
    • James Murray
    • James Murray
    • E21B33/12
    • E21B33/124E21B33/128
    • A well casing packer is provided that includes a seal mandrel having a first coupler, a second coupler, and a neck extending between the first coupler and the second coupler. A first compression body is slidably coupled to the seal mandrel at the first coupler. A second compression body is connected to the seal mandrel, and a compression lock ring connected to the first compression body. A packer seal is disposed in surrounding relation to a portion of the neck of the seal mandrel and between the second compression body and the compression lock ring, such that a longitudinal movement of the seal mandrel with respect to the first compression body allows the second compression body and the compression lock ring to longitudinally compress and radially expand the packer seal.
    • 提供一种套管封隔器,其包括具有第一联接器,第二联接器和在第一联接器和第二联接器之间延伸的颈部的密封心轴。 第一压缩体在第一耦合器处可滑动地联接到密封心轴。 第二压缩体连接到密封心轴,以及与第一压缩体连接的压缩锁定环。 封隔器密封件围绕密封心轴的颈部的一部分设置在第二压缩体和压缩锁定环之间,使得密封心轴相对于第一压缩体的纵向运动允许第二压缩 主体和压缩锁定环以纵向压缩和径向扩张封隔器密封件。
    • 49. 发明申请
    • Recovering materials
    • 回收材料
    • US20050189109A1
    • 2005-09-01
    • US10509281
    • 2003-03-28
    • Donald EaglandNicholas CrowtherJames MurrayAustin Tobin
    • Donald EaglandNicholas CrowtherJames MurrayAustin Tobin
    • C08F2/10C09K8/588E21B43/16
    • C09K8/588
    • A process for recovering materials from a subterranean formation, for example in enhanced oil recovery, comprises: (A) (a) (i) selecting a first polymeric material having a repeat unit of formula (A) wherein A and B are the same or different, are selected from optionally-substituted aromatic and heteroaromatic groups and at least one comprises a relatively polar atom or group and R1 and R2 independently comprise relatively non-polar atoms or groups; or (ii) selecting a first polymeric material prepared or preparable by providing a compound of general formula (B) wherein A, B, R1 and R2 are as described above, in an aqueous solvent and causing the groups C═C in said compound to react with one another to form said first polymeric material; (b) selecting a second polymeric material which includes a functional group which is able to react in the presence of said first polymeric material to form a third polymeric material; (c) causing the formation of said third polymeric material by a reaction involving said first and second polymeric materials; and (d) contacting the subterranean formation with said third polymeric material; or (B) contacting the formation with a polymeric material (hereinafter “said third polymer material”) which is a product of a reaction involving: (a) a first polymeric material as described in (A) (a) (i) or (ii); and (b) a second polymeric material which includes a functional group which is able to react in the presence of said first polymeric material to form said third polymeric material.
    • (A)(a)(i)选择具有式(A)的重复单元的第一聚合物材料,其中A和B相同,或者 不同的,选自任选取代的芳族和杂芳族基团,并且至少一个包含相对极性的原子或基团,并且R 1和R 2独立地包含相对非极性的原子 或组; 或(ii)选择通过提供通式(B)的化合物制备或制备的第一聚合物材料,其中A,B,R 1和R 2如上所述 在水性溶剂中并使所述化合物中的基团CC彼此反应以形成所述第一聚合物材料; (b)选择第二聚合物材料,其包括能在所述第一聚合物材料存在下反应形成第三聚合物材料的官能团; (c)通过涉及所述第一和第二聚合物材料的反应引起所述第三聚合物材料的形成; 和(d)使所述地层与所述第三聚合物接触; 或(B)使该地层与聚合物材料(以下称为“所述第三聚合物材料”)接触,所述聚合物材料是反应产物,该反应涉及:(a)如(A)(a)(i)或( ii); 和(b)第二聚合物材料,其包括能够在所述第一聚合物材料存在下反应以形成所述第三聚合物材料的官能团。
    • 50. 发明授权
    • Treatment of arthritis disorders, rheumatoid arthritis and manifestations associated with rheumatoid disorders
    • 治疗关节炎疾病,类风湿关节炎和与类风湿病有关的表现
    • US06358941B1
    • 2002-03-19
    • US09125306
    • 1999-05-03
    • Ernir SnorrasonJames Murray
    • Ernir SnorrasonJames Murray
    • A01N5718
    • A61K31/662A61K31/407A61K31/435A61K31/473A61K31/55Y10S514/923
    • The present invention relates to the use of pharmaceutically acceptable cholinesterase inhibitors for the preparation of a pharmaceutical composition for the treatment or prophylaxis of arthritic disorders, including osteoarthritis, rheumatoid arthritis and other rheumatoid diseases such as Juvenile Arthritis, Systemic Lupus Erythematosis, Sjogren's Syndrome, Progressive Systemic Sclerosis, Polymyositis, Dermatomyositis, Ankylosing Spondilitis, Reiter's Syndrome, Psoriatic Arthritis, Relapsing Polychondritis, Relapsing Panniculitis, Crohn's Disease, Ulcerative Colitis, Heredity Complement Deficiencies, Collagen Vascular Diseases, Felty's Syndrome, rheumatological manifestations associated with bacterial and viral endocarditis or myocarditis and other rheumatological manifestations such as anaemia of chronic disorders. The invention also relates to a novel method of treatment or prophylaxis of such diseases and manifestations. Preferably, the cholinesterase inhibitors are selected from a group of nicotinic acetylcholinesterase inhibitors such as galantamine (the name of this drug was previously spelled galanthamine).
    • 本发明涉及药学上可接受的胆碱酯酶抑制剂在制备用于治疗或预防关节炎疾病,包括骨关节炎,类风湿性关节炎和其他类风湿性疾病如青少年关节炎,系统性红斑狼疮,干燥综合征,进行性疾病 系统性硬化症,多发性肌炎,皮肌炎,强直性脊柱炎,赖特综合征,银屑病关节炎,复发性软骨炎,复发性脂膜炎,克罗恩病,溃疡性结肠炎,遗传性补体缺陷,胶原血管疾病,Felty综合征,与细菌和病毒性心内膜炎或心肌炎相关的风湿病学表现, 其他风湿病表现,如慢性疾病的贫血。 本发明还涉及一种治疗或预​​防这些疾病和表现的新方法。 优选地,胆碱酯酶抑制剂选自一组烟碱乙酰胆碱酯酶抑制剂,例如加兰他敏(该药物的名称以前是加兰他敏片)。